Literature DB >> 25314016

Sorting out the risks in progressive multifocal leukoencephalopathy.

Leonard H Calabrese1, Eamonn Molloy2, Joseph Berger3.   

Abstract

Progressive multifocal leukoencephalopathy (PML) is a rare, opportunistic infection of the central nervous system, caused by reactivation of the ubiquitous JC virus. PML is a devastating disease that is frequently fatal, and although survival rates have improved, patients who survive PML often experience considerable neurological deficits. PML was associated with a variety of immunosuppressive therapies in the past decade, but attribution of causality is difficult owing to the presence of confounding factors and to an inadequate understanding of the underlying pathogenesis of this disease. This uncertainty has hindered efforts for shared decision-making between physicians and their patients and, in some cases, discouraged the use of potentially beneficial therapies. We propose a categorization of immunosuppressive agents according to their risk of PML to support a better-informed decision-making process when evaluating the risks and benefits of these therapies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25314016     DOI: 10.1038/nrrheum.2014.167

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


  33 in total

Review 1.  The pathogenesis of progressive multifocal leukoencephalopathy.

Authors:  Joseph R Berger; Kamel Khalili
Journal:  Discov Med       Date:  2011-12       Impact factor: 2.970

2.  Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.

Authors:  Gert Van Assche; Marc Van Ranst; Raf Sciot; Bénédicte Dubois; Séverine Vermeire; Maja Noman; Jannick Verbeeck; Karel Geboes; Wim Robberecht; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2005-06-09       Impact factor: 91.245

3.  The basis for modeling progressive multifocal leukoencephalopathy pathogenesis.

Authors:  Joseph R Berger
Journal:  Curr Opin Neurol       Date:  2011-06       Impact factor: 5.710

Review 4.  Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies.

Authors:  L H Calabrese; E S Molloy
Journal:  Ann Rheum Dis       Date:  2008-12       Impact factor: 19.103

5.  The bone marrow, B cells, and JC virus.

Authors:  Sidney A Houff; Joseph R Berger
Journal:  J Neurovirol       Date:  2008-10-16       Impact factor: 2.643

Review 6.  PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section.

Authors:  Joseph R Berger; Allen J Aksamit; David B Clifford; Larry Davis; Igor J Koralnik; James J Sejvar; Russell Bartt; Eugene O Major; Avindra Nath
Journal:  Neurology       Date:  2013-04-09       Impact factor: 9.910

7.  Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis.

Authors:  David B Clifford; Beau Ances; Craig Costello; Shari Rosen-Schmidt; Magnus Andersson; Deborah Parks; Arie Perry; Raju Yerra; Robert Schmidt; Enrique Alvarez; Kenneth L Tyler
Journal:  Arch Neurol       Date:  2011-05-09

8.  Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases.

Authors:  Eamonn S Molloy; Leonard H Calabrese
Journal:  Arthritis Rheum       Date:  2009-12

9.  JC virus antibody status underestimates infection rates.

Authors:  Joseph R Berger; Sidney A Houff; Julie Gurwell; Nubia Vega; Craig S Miller; Robert J Danaher
Journal:  Ann Neurol       Date:  2013-08-06       Impact factor: 10.422

10.  Detection of JC virus DNA in human tonsil tissue: evidence for site of initial viral infection.

Authors:  M C Monaco; P N Jensen; J Hou; L C Durham; E O Major
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

View more
  10 in total

1.  Quantitative Proteomic Analysis of Enriched Nuclear Fractions from BK Polyomavirus-Infected Primary Renal Proximal Tubule Epithelial Cells.

Authors:  Joshua L Justice; Brandy Verhalen; Ranjit Kumar; Elliot J Lefkowitz; Michael J Imperiale; Mengxi Jiang
Journal:  J Proteome Res       Date:  2015-09-23       Impact factor: 4.466

Review 2.  Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs.

Authors:  Emanuele D'Amico; Aurora Zanghì; Carmela Leone; Hayrettin Tumani; Francesco Patti
Journal:  Drug Saf       Date:  2016-12       Impact factor: 5.606

Review 3.  Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases.

Authors:  Robbert-Jan Gieselbach; Annemarie H Muller-Hansma; Martijn T Wijburg; Marjolein S de Bruin-Weller; Bob W van Oosten; Dennis J Nieuwkamp; Frank E Coenjaerts; Mike P Wattjes; Jean-Luc Murk
Journal:  J Neurol       Date:  2017-05-23       Impact factor: 4.849

Review 4.  Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy.

Authors:  Leslie S Kean; Laurence A Turka; Bruce R Blazar
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

5.  Adipocyte Plasma Membrane Protein (APMAP) promotes JC Virus (JCPyV) infection in human glial cells.

Authors:  Sheila A Haley; Bethany A O'Hara; Walter J Atwood
Journal:  Virology       Date:  2020-06-07       Impact factor: 3.616

Review 6.  Is there a (host) genetic predisposition to progressive multifocal leukoencephalopathy?

Authors:  Eli Hatchwell
Journal:  Front Immunol       Date:  2015-05-11       Impact factor: 7.561

7.  Evaluation of Facebook and Twitter Monitoring to Detect Safety Signals for Medical Products: An Analysis of Recent FDA Safety Alerts.

Authors:  Carrie E Pierce; Khaled Bouri; Carol Pamer; Scott Proestel; Harold W Rodriguez; Hoa Van Le; Clark C Freifeld; John S Brownstein; Mark Walderhaug; I Ralph Edwards; Nabarun Dasgupta
Journal:  Drug Saf       Date:  2017-04       Impact factor: 5.606

Review 8.  Infection and Lupus: Which Causes Which?

Authors:  Sarah Doaty; Harsh Agrawal; Erin Bauer; Daniel E Furst
Journal:  Curr Rheumatol Rep       Date:  2016-03       Impact factor: 4.686

9.  Simultaneous Development of Progressive Multifocal Leukoencephalopathy and Cryptococcal Meningitis during Methotrexate and Infliximab Treatment.

Authors:  Yasunobu Nosaki; Ken Ohyama; Maki Watanabe; Takamasa Yokoi; Kazuo Nakamichi; Masayuki Saijo; Yoshiharu Miura; Katsushige Iwai
Journal:  Intern Med       Date:  2019-09-15       Impact factor: 1.271

10.  Progressive multifocal leukoencephalopathy following five lines of therapy and three autologous bone marrow transplants for multiple myeloma.

Authors:  Kathryn Knight; Siobhan Chien; Ioannis Koutsavlis; Victoria Campbell
Journal:  BMJ Case Rep       Date:  2020-03-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.